ORIGINAL RESEARCH

To Investigate The Platelet Count In Pregnant Women

Dr. Sonal Dhingra

Assistant Professor, Department of Pathology, NCR Medical College, Hapur, Uttar Pradesh, India

Correspondence:

Dr. Sonal Dhingra

Assistant Professor, Department of Pathology, NCR Medical College, Hapur, Uttar Pradesh, India

Received: 24 November, 2022 Accepted: 21 December, 2022

ABSTRACT

Aim: The purpose of

this research was to investigate the platelet count in pregnant women. Methods: This cross-sectional study was carried out in the Department of Pathology. Total 100 patients were divided in two groups as Cases and Control. Cases study group includes 50 females with the thrombocytopenia and Control includes 50 females without thrombocytopenia.

Results: The data from the 100 pregnant females were collected and presented as below. The study population was divided in two groups as Cases and Control. Cases study group includes 50 females with the thrombocytopenia and Control includes 50 females without thrombocytopenia. The Most effective age group in which thrombocytopenia seen was between 20 to 25 years. Out of 100 patients with thrombocytopenia, mild preeclampsia was present in 22 cases (44%) and while the rest 28(56%) had Severe Pre eclampsia with thrombocytopenia. In women with Mild Pre eclampsia Platelet Count (x 109/L) was 65-277, Severe Pre eclampsia Platelet Count (x109/L) was 27-249 and women without thrombocytopenia had normal Platelet Count .

Conclusion: We concluded that the clinically platelet indices can be a useful screening test for early identification of preeclampsia and eclampsia. Also platelet indices can assess the prognosis of this disease in pregnant women and can be used as an effective prognostic marker because it correlates with severity of the disease.

Keywords - Eclampsia, platelets, Pre-eclampsia, Pregnancy

INTRODUCTION

Beginning in 1993, three large studies documented that 5 to 10% of women who had uncomplicated pregnancies had a platelet count of less than 150,000 per cubic millimeter at the time of delivery which was described as gestational thrombocytopenia. The normal distribution of platelet counts at the time of delivery and the absence of health problems in the mother and infant suggested that gestational thrombocytopenia was the result of lower platelet counts that occur in all women during pregnancy. Gestational thrombocytopenia is a condition that commonly affects pregnant women. Thrombocytopenia is defined as the drop in platelet count from the normal range of $150,000 - 400,000 / \mu L$ to a count lower than 150,000 / Ml. There is still ongoing research to determine the reason for the lowering of platelet count in women with a normal pregnancy. Some researchers speculate the cause to be dependent on dilution, decreased production of platelets, or an increased turnover event.

Although women with normal pregnancy experience a low platelet count, women experiencing a continuous drop in platelet will be diagnosed with thrombocytopenia and women with levels greater than 70,000 / µL will be diagnosed with gestational thrombocytopenia. Thrombocytopenia affects approximately 7-10% of pregnant women and of the 7-10%, within that population; approximately 70-80% have gestational thrombocytopenia. Gestational Thrombocytopenia is a disorder similar to immune thrombocytopenia (ITP) and is difficult to differentiate between the two disorders. Therefore, a medical history is conducted to because a diagnostic test is unavailable. Generally, there is a decrease in platelet count in pregnant women and it will be due to many reasons.⁵ The two main causes of thrombocytopenia are a decrease in the production of platelets in the bone marrow and an increase in the destruction of the platelets.⁶ Platelets, along with other components of the blood, are produced in the spongy tissue found in the bone, known as bone marrow. Low platelet count maybe due to the decreased production of platelets in the bone marrow. A decreased production would be due to vitamin B12 deficiency, iron deficiency, viral infections, chemotherapy, alcohol consumption, leukemia, aplastic anemia. myelodysplasia, and cirrhosis. During pregnancy, the fetus' waste products diffuse into the mother's sinuses (blood stream), and cause the mother's spleen to become overactive and enlarged. Normally, the spleen filters and removes the waste products and with the overload of unwanted substances in the bloodstream, the spleen will remove blood cells too quickly⁸ or store the platelets. In both cases, the overactive spleen would cause a decrease in the circulation of the platelets.⁶ Pre-eclampsia (PE) is a serious multi-systemic pregnancy complication affecting between (5-8 %) worldwide.^{9,10} Generally the diagnosis depends mainly on finding of hypertension and proteinuria after 20 weeks of pregnancy. ¹¹ considered as one of the major health problems associated with pregnancy and one of the causes of maternal mortality. 12,13 Thrombocytopenia carries a risk for both the mother and her fetus, associated with substantial maternal or neonatal morbidity & mortality. Therefore it is of utmost importance to institute specific therapies promptly and improve the maternal and neonatal outcome. Hence this study was done to know the incidence of thrombocytopenia in pregnancy induced hypertension and its effect on maternal and fetal outcome.

MATERIAL AND METHODS

This cross-sectional study was carried out in the Department of Pathology, after taking the approval of the protocol review committee and institutional ethics committee. After taking informed consent detailed history was taken from the patient or the relatives if the patient was not in good condition. Total 100 patients was divided in two groups as Cases and Control. Cases study group includes 50 females with the thrombocytopenia and Control includes 50 females without thrombocytopenia. All the subjects were undergone blood investigations, i.e. complete blood cell count for Platelet count using EDTA anticoagulant blood and analysed on Automated Haematology Analyser. The test was conducted within 1 hour of sample collection maintaining at room temperature to minimize variation due to sample aging. All pregnant women with pregnancy induced hypertension and Gestational age above 20 weeks were included in this study. Patients with established coagulation and haematological disorders, Gestational age below 20 weeks or chronic hypertension and Pre-existing renal or vascular diseases, seizure disorders, severe anaemia, and liver diseases were excluded from the study.

RESULTS

The data from the 100 pregnant females were collected and presented as below. The study population was divided in two groups as Cases and Control. Cases study group includes 50

females with the thrombocytopenia and Control includes 50 females without thrombocytopenia.

The Most effective age group in which thrombocytopenia seen was between 20 to 25 years. Table 1shows that age was an important criterion and there was difference in the occurrence of thrombocytopenia in different age groups.

Table 1: Demographic profile of patients

Age	Cases: with thrombocytopenia	Control without	Total
	N=50	thrombocytopenia	N=100
		N=50	
Below 20 years	16	11	27
20-25 years	26	24	50
25-30 years	5	11	16
>30 years	3	4	7
Parity			
Primi	39	35	74
Multi	11	15	26

Out of 100 patients with thrombocytopenia, mild preeclampsia was present in 22 cases (44%) and while the rest 28(56%) had Severe Pre eclampsia with thrombocytopenia.

Table 2: Distribution of Mild Pre eclampsia and Severe Pre eclampsia with thrombocytopenia

Conditions	Mild Pre eclampsia	%	Severe Pre eclampsia	%
thrombocytopenia	22	44	28	56

Table 3: Distribution of cases and controls in relation to gestational age

Condition	No. of Cases	Gestational Age
Thrombocytopenia with	22	29-37
Mild Pre eclampsia		
Thrombocytopenia with	28	30-38
Severe Pre eclampsia		
Controls	50	28-37
Total	100	

In women with Mild Pre eclampsia Platelet Count (x 109/L) was 65-277, Severe Pre eclampsia Platelet Count (x 109/L) was 27-249 and women without thrombocytopenia had normal Platelet Count.

Table 4: Mean platelet count in cases and controls

Conditions	No. of Cases	Platelet Count (x 109/L)
Thrombocytopenia with	22	65-277
Mild Pre eclampsia		
Thrombocytopenia with	28	27-249
Severe Pre eclampsia		
Controls	50	79-437

DISCUSSION

It appears that as far as age is concerned, there is no or little difference between normal healthy pregnant women and patients with different degrees of severity of pregnancy induced hypertension. But it was clear that most patients in normal pregnant control group and patients with pregnancy induced hypertension were in age ranging between 20 to 30 years. Jaleel *et al* and Kumar *et al* also found maximum cases between 21-30 years of age, similar to the present findings. Younger age of occurrence of preeclampsia testifies the early age of marriage and pregnancy in our country as compared to western countries.

The comparison of platelet count amongst the subgroups of cases showed the decrease in platelet count in severer eclampsia was significant when compared with that in mild preeclampsia. The comparison of platelet count amongst the subgroups of cases showed the decrease in platelet count in severer eclampsia was significant when compared with that in mild preeclampsia. This high incidence may be explained due to hospital admission of only those patients who are willing for admission and are ill enough to seek for hospital care. The use of thrombocytopenia as a screening test for severity of pregnancy induced hypertension has not been well documented in the literature. Redman et al reported decreased platelet count in women who developed preeclampsia and stated that increased platelet consumption is an early feature of this disorder. Galton et al claimed that the severity of thrombocytopenia correlates with severity of hypertension. ¹⁷ Romero et al reported that women with pre eclampsia and thrombocytopenia have higher incidence of maternal and neonatal complications. ¹⁸ Preeclampsia is one of the commonest medical disorders during pregnancy and affects approximately 5-10% of all pregnancies mostly affecting the primigravida. It continues to be major causes of maternal and perinatal morbidity and mortality.¹⁹ It is a multisystem disease and many theories are proposed for pathophysiology. So there is a constant search for better prognostic factors to predict the progression and severity of disease. Activation of coagulation, fibrinolysis, platelet and vascular endothelial function are believed to play an important role in pathogenesis of preeclampsia. The fall in platelet count is most frequently found in preeclampsia and is probably due to consumption during low grade intravascular coagulation.²⁰ In a study from Bhopal by Anand and Kirshnanand et al.,²¹ majority of the cases had preeclampsia (66.36%) and the rest eclampsia (33.64%). Wolde et al.²² study showed preeclampsia as the most common hypertensive disorder of pregnancy (51.9%); followed by eclampsia (23.4%), HELLP syndrome (8.9%), mild preeclampsia (7.6%), and simple gestational HTN (5.1%). In our study, most cases belonged to the mild preeclampsia (44%) group followed by cases with severe preeclampsia (56%). Because thrombocytopenia can be induced acutely by pre eclampsia – eclampsia, the platelet count is routinely measured in hypertensive pregnant women. The frequency and intensity of maternal thrombocytopenia varies and likely is dependent on the intensity of the disease process, duration of pre eclampsia, and the frequency with which platelet count are performed. Overt thrombocytopenia, defined by a platelet count less than 100,000/mm³ indicates severe disease. In most cases, delivery is indicated because the platelet count continues to decrease. After delivery, the platelet count increases progressively reach a normal level within 3 to 5 days.

CONCLUSION

We concluded that the clinically platelet indices can be a useful screening test for early identification of preeclampsia and eclampsia. Also platelet indices can assess the prognosis of this disease in pregnant women and can be used as an effective prognostic marker because it correlates with severity of the disease.

REFERENCE

1. Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med. 1993; 329:1463–6.

- 2. Boehlen F, Hohlfeld P, Extermann P, Perneger TV, de Moerloose P. Platelet count at term pregnancy: a reappraisal of the threshold. Obstet Gynecol. 2000; 95:29–33.
- 3. Perepu U, Rosenstein L. Maternal thrombocytopenia in pregnancy. ProcObstet Gynecol. 2013; 3(1):6:15. Available from: http://ir.uiowa.edu/pog/. Free full text article
- 4. Mccrae Keith R. Thrombocytopenia in Pregnancy. Platelets. 2013, 909-28.
- 5. Clinical. Practice Guide on. Thrombocytopenia in Pregnancy. Presented by the American. Society of Hematology. Anita Rajasekhar, MD, MS, 2013.
- 6. "Thrombocytopenia (low platelet count) Symptoms Mayo Clinic". www.mayoclinic.org. Retrieved 2015.
- 7. Low Platelet Count (Thrombocytopenia). Healthline. Retrieved, 2015.
- 8. Hypersplenism: Medline Plus Medical Encyclopedia. www.nlm.nih.gov. Retrieved, 2015
- 9. Sibai B, Dekker G, Kupferminc M. Preeclampsia. Lancet, 365, 2005, 785–799.
- 10. Stekkinger E, Zandstra M, Peeters LL, Spaandernen ME. Early-onset preeclampsia and the prevalence of postpartum metabolic syndrome. Obstet Gynaecol, 114(5), 2009, 1076-1084.
- 11. Semenovakaya Z and Erogul M. Pregnancy, Preeclampsia. eMedicine Medical Reference, 2010,
- 12. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look P. WHO analysis of causes of maternal death: a systemic review. Lancet, 367(9516), 2006,1066-1074.
- 13. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol, 33, 2009, 130–137.
- 14. Jaleel A, Baseer A. Thrombocytopenia in preeclampsia: an earlier detector of HELLP syndrome. JPMA. J Pak Med Assoc. 1997; 47(9):230-2.
- 15. Kumar PL, Nirmala T, Vani BR, Murthy Srinivasa V, Geetha RL. Study of coagulation profile in pregnancy induced hypertension (PIH). Indian J Pathol Oncol. 2015:2(1):1-6.
- 16. Redman CW. Early platelet consumption in preeclampsia. Br J med. 1978; 70:334-8.
- 17. Galton M. Coagulation studies on the peripheral circulation of patients with toxemia of pregnancy. J Reprod med. 1971; 6:89-100.
- 18. Romero R. Clinical significance, prevalence and natural history of thrombocytopenia in pregnancy induced hypertension. Am J perinatal? 1989; 6:32-8.
- 19. Robert JM, Cooper DW. Pathogenesis and genetic of preeclampsia. Lancet 2001; 357 (9249): 53 56.
- 20. Dadhich S, Agrawal S, Soni M, Choudhary R, Jain R, Sharma S et al. Predictive value of platelet indices in development of preeclampsia. J SAFOG. 2012; 4(1):17-21
- 21. Anand S, Kirshnanand. Perinatal outcome in growth retarded babies born to normotensive and hypertensive mothers: A prospective study. People's J Sci Res 2012;5:24-8.
- 22. Wolde Z, Segni H, Woldie M. Hypertensive disorders of pregnancy in Jimma University specialized hospital. Ethiop J Health Sci 2011;21:147-54.